ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Mar 09, 2018 8:58pm

149 Views

Post# 27695567

RE:Anavex versus Promis

"Sorry but PMN will go back to where it was $0.24"

I've said it before and I'll say it again - the share price has nothing to do with the value of this company. Doesn't matter if the share price goes back to 20 cents or if it goes to a dollar. The ultimate value will be determined on other factors. The share price matters from the perspective of private finacing and dilution, the share price matters when you're buying your shares and as much as I like seeing my investment in the green it's essentially a meaningless number.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale